Table 2.
Agents | Mechanism | Effect | Indications | Considerations |
---|---|---|---|---|
Phenylephrine | A1 agonist | Vasoconstriction | Various forms of shock | Caution in cardiac dysfunction as it increases afterload |
Norepinephrine | A<B agonist | Inotropy, chronotropy, dromotropy, and vasoconstriction | Most common first line agent in shock | Most benefits demonstrated in septic shock |
Epinephrine | A≪B agonist | Inotropy, chronotropy, dromotropy, and vasoconstriction | Commonly used as second line agent or first line in anaphylactic shock | Surviving Sepsis Guidelines has most data for epinephrine as second line agent |
Dopamine | Dose dependent A, B, and D agonism | Inotropy, dromotropy, chronotropy, and vasoconstriction (at highest doses) | Second line agent in most forms of shock | SOAP II trial demonstrated more incidence of tachy‐arrythmias and increased mortality in CS patients when dopamine was used as first line |
Vasopressin | V1 agonist | Vasoconstriction | Second line agent in most forms of shock | On or Off dosing, can cause hyponatremia |
Dobutamine | B agonist | Inotropy and mild vasodilation | Commonly used in cardiogenic shock | May contribute to hypotension |
Levosimendan | Myofilament Ca2+ sensitizer and K+ channel modifier | Ionotropy and inodilator | Used in acutely decompensated chronic heart failure | Minimal effect on myocardial oxygen consumption |
CS indicates cardiogenic shock; SOAP, Sepsis Occurrence in Acutely Ill Patients.